Skip to content

Study · Systematic review · 2017

4 results

Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.

Monami M, Dicembrini I, Nreu B, Andreozzi F, Sesti G, Mannucci E

Acta diabetologica20 Sept 2017Cited by 24 (Europe PMC)

PMID28932989 (opens in a new tab)DOI10.1007/s00592-017-1054-2 (opens in a new tab)PepBankPUB-28932989
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In the pooled trials, liraglutide could be less effective on HbA1c in non-Caucasians and older patients.

    In plain wordsIn the pooled trials, liraglutide might work less well in non-Caucasian and older patients.

    Peptide
    Liraglutide
    Outcome
    MixedLiraglutide efficacy in non-Caucasians and older patients
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas in non-Caucasians and older patients liraglutide could be less effective.
    1 context sentence
    Summary · context
    A Medline and Embase search for "exenatide" OR "liraglutide" OR "albiglutide" OR "dulaglutide" OR "lixisenatide" was performed, collecting randomized clinical trials (duration > 12 weeks) up to September 2016, comparing GLP-1 RA at the maximal approved dose with placebo or active drugs.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In placebo-controlled trials, pooled GLP-1 receptor agonists reduced HbA1c at 24 weeks versus placebo (41 trials).

    In plain wordsIn trials, GLP-1 drugs as a group lowered HbA1c more than placebo at 24 weeks.

    Peptide
    Liraglutide
    Outcome
    Decrease24-week HbA1c reduction, pooled GLP-1 receptor agonists
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In placebo-controlled trials (n = 41), the 24-week mean reduction of HbA1c with GLP-1 RA was - 0.75 [- 0.87; - 0.63]%.
    1 context sentence
    Summary · context
    A Medline and Embase search for "exenatide" OR "liraglutide" OR "albiglutide" OR "dulaglutide" OR "lixisenatide" was performed, collecting randomized clinical trials (duration > 12 weeks) up to September 2016, comparing GLP-1 RA at the maximal approved dose with placebo or active drugs.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    Across GLP-1 receptor agonists, shorter-acting molecules appeared more effective in patients with lower fasting glucose, and longer-acting agents in patients with higher fasting glucose.

    In plain wordsAcross GLP-1 drugs as a group, short-acting ones seemed to work better with lower fasting glucose and long-acting ones with higher fasting glucose.

    Peptide
    Liraglutide
    Outcome
    MixedEfficacy by fasting glucose and action duration, pooled GLP-1 receptor agonists
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Shorter-acting molecules appear to be more effective in patients with lower fasting glucose, whereas longer-acting agents in patients with higher fasting hyperglycaemia.
    1 context sentence
    Summary · context
    A Medline and Embase search for "exenatide" OR "liraglutide" OR "albiglutide" OR "dulaglutide" OR "lixisenatide" was performed, collecting randomized clinical trials (duration > 12 weeks) up to September 2016, comparing GLP-1 RA at the maximal approved dose with placebo or active drugs.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    Across GLP-1 receptor agonists, obesity and duration of diabetes did not appear to moderate the HbA1c efficacy.

    In plain wordsAcross GLP-1 drugs as a group, body weight and how long someone had diabetes did not seem to change how well the drugs worked.

    Peptide
    Liraglutide
    Outcome
    No significant changeModeration of efficacy by obesity and diabetes duration, pooled GLP-1 receptor agonists
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Obesity and duration of diabetes do not seem to moderate the efficacy of GLP-1 RA
    1 context sentence
    Summary · context
    A Medline and Embase search for "exenatide" OR "liraglutide" OR "albiglutide" OR "dulaglutide" OR "lixisenatide" was performed, collecting randomized clinical trials (duration > 12 weeks) up to September 2016, comparing GLP-1 RA at the maximal approved dose with placebo or active drugs.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.